Trade Gyre Therapeutics Inc - GYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0768 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.6566 |
| Open | 7.8166 |
| 1-Year Change | -55% |
| Day's Range | 6.1466 - 7.8166 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 7.6566 | -1.2300 | -13.84% | 8.8866 | 8.9366 | 6.9566 |
| Mar 28, 2025 | 9.0466 | 0.0700 | 0.78% | 8.9766 | 9.0666 | 8.8066 |
| Mar 27, 2025 | 9.0166 | 0.1600 | 1.81% | 8.8566 | 9.3666 | 8.8566 |
| Mar 26, 2025 | 8.7366 | -0.5600 | -6.02% | 9.2966 | 9.3966 | 8.6166 |
| Mar 25, 2025 | 9.4166 | 0.3000 | 3.29% | 9.1166 | 9.4266 | 8.7666 |
| Mar 24, 2025 | 9.1266 | -0.5500 | -5.68% | 9.6766 | 9.9266 | 9.0366 |
| Mar 21, 2025 | 9.6466 | -0.1400 | -1.43% | 9.7866 | 10.0166 | 9.5666 |
| Mar 20, 2025 | 10.1366 | 0.0700 | 0.70% | 10.0666 | 10.4366 | 9.6866 |
| Mar 19, 2025 | 10.2166 | 1.4800 | 16.94% | 8.7366 | 10.2966 | 8.7366 |
| Mar 18, 2025 | 8.4766 | -2.7100 | -24.23% | 11.1866 | 11.1866 | 8.4466 |
| Mar 17, 2025 | 12.1866 | 0.2100 | 1.75% | 11.9766 | 12.2766 | 11.6766 |
| Mar 14, 2025 | 12.0766 | 0.1500 | 1.26% | 11.9266 | 12.5266 | 11.9266 |
| Mar 13, 2025 | 11.8766 | 0.3100 | 2.68% | 11.5666 | 11.9666 | 11.4666 |
| Mar 12, 2025 | 11.6066 | 0.2400 | 2.11% | 11.3666 | 12.1166 | 11.3266 |
| Mar 11, 2025 | 11.2866 | 0.5000 | 4.64% | 10.7866 | 11.9666 | 10.7866 |
| Mar 10, 2025 | 10.2666 | 0.2000 | 1.99% | 10.0666 | 10.2766 | 9.0766 |
| Mar 7, 2025 | 10.2866 | -2.2800 | -18.14% | 12.5666 | 13.4166 | 9.8566 |
| Mar 6, 2025 | 10.6166 | -0.2500 | -2.30% | 10.8666 | 11.0766 | 10.5966 |
| Mar 5, 2025 | 11.0866 | 0.3800 | 3.55% | 10.7066 | 11.1666 | 10.3666 |
| Mar 4, 2025 | 10.8666 | 0.0800 | 0.74% | 10.7866 | 11.0766 | 10.5466 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Biosciences, Inc. Company profile
About Catalyst Biosciences Inc
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).
Equity composition
Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com